Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
SAINT in Postpartum Depression (PPD)
NCT07210255 · View on ClinicalTrials.gov ↗
Study Summary
This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively reduce symptoms of postpartum depression (PPD) compared to a sham treatment. It will enroll 192 women within 12 months postpartum who are experiencing depression that has not improved with standard care, and will track their progress for up to 12 months. The trial's main goal is to see if SAINT leads to reduction in depression severity in women with postpartum depression.
Conditions Studied
Interventions
- DEVICE SAINT Neuromodulation System
- DEVICE Sham SAINT Stimulation
Study Locations (4)
Massachusetts
- UMass Chan Medical School — Worcester
New York
- Icahn School of Medicine at Mount Sinai — New York
South Carolina
- The Medical University of South Carolina (MUSC) — Charleston
Texas
- University of Texas at Austin, Dell Medical School, Health Discovery Building — Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2029-10-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210255
The ClinicalTrials.gov registry entry for NCT07210255 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Magnus Medical, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Postpartum Depression (PPD) appearing as the primary indexed condition, and to 2 interventions — of which SAINT Neuromodulation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07210255 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Massachusetts, New York, South Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07210255 about?
NCT07210255 is a clinical study titled "SAINT in Postpartum Depression (PPD)". This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively reduce symptoms of postpartum depression (PPD) compared to a sham treatme...
What is the current status of trial NCT07210255?
This trial is currently recruiting. It is a NA study. The enrollment target is 192 participants. The study started on 2025-11-01. Estimated completion is 2029-10-31.
What conditions does trial NCT07210255 study?
This clinical trial studies the following conditions: Postpartum Depression (PPD). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07210255?
The interventions under investigation include: SAINT Neuromodulation System (DEVICE), Sham SAINT Stimulation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07210255?
This trial is sponsored by Magnus Medical, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07210255 being conducted?
This trial has 4 study locations across Massachusetts, New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.